Adaptimmune Therapeutics plc Stock News

Shares of Adaptimmune Therapeutics PLC tumbled 11% in premarket trading Monday, after the biopharmaceutical company focused on cancer treatments said it planned a public offering of 12.5 million shar

Adaptimmune Therapeutics plc (“Adaptimmune”)(ADAP), a leader in cell therapy to treat cancer, today announced that it intends to offer and sell 12,500,000 American Depositary Shares (“ADSs”) i

Shares in UK-based biopharma Adaptimmune (ADAP) spiked 127% in Friday’s trading, after the company reported positive durability and efficacy data in synovial sarcoma at the American Society for Clin

Stocks pared back losses Friday after President Donald Trump delivered a China-focused speech that was more restrained than expected. There was no talk of sanctions or raised tariffs on Chinese goods.

Positive results from a handful of patients treated have bolstered confidence in the company's cell-based approach to cancer treatment.

(Bloomberg) -- Biotechnology stocks saw broad swings Friday morning as investors worked their way through a deluge of data from cancer drug developers presenting at the American Society of Clinical On

The company presented positive data on its experimental cell therapy, which is designed to treat a range of cancers.

- New Phase 2 trial in EGJ cancer planned for 1H 2021, after first two patients treated responded to next-generation ADP-A2M4CD8 therapy - - Durability and efficacy data.

Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector. Surface Oncology Inc (...

Focused on using engineering cells to help the immune system recognize and fight cancer, the company made waves when it showed activity against solid tumors. The engineered T cells increase the immun

Q1 2020 Adaptimmune Therapeutics PLC Earnings Call

Image source: The Motley Fool. Adaptimmune Therapeutics PLC (NASDAQ: ADAP)Q1 2020 Earnings CallMay 14, 2020, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepare

Shares of Adaptimmune Therapeutics (NASDAQ:ADAP) rose 1.3% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were flat 0.00% year over year to ($0.04), w

- Upfront payment of $50m received from Astellas and approximately $90m offering completed -             - Financial guidance confirmed: funded into 2H 2021 - - Orphan Drug.

- Edited stem-cell derived T-cells can kill MAGE-A4+ cancer targets in vitro - - T-cell receptor expression edited in to stem cells - a milestone to build cell banks for.